Towards establishing the standard of care for second-line therapy in advanced biliary tract cancer
Mené sur 174 patients atteints d'un cancer des voies biliaires de stade métastatique, cet essai multicentrique de phase IIB évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout de l'irinotécan sous forme liposomale à un traitement de seconde ligne combinant fluorouracile et leucovorine, après l'échec d'un traitement à base de gemcitabine et cisplatine
The prognosis of patients with advanced biliary tract cancer is poor. Preferred first-linechemotherapy for these patients is a combination of gemcitabine plus cisplatin, followingthe results of the ABC-02 trial. The ABC-06 trial compared active symptom control with active symptom control and FOLFOX (fluorouracil,leucovorin, and oxaliplatin) in patients with advanced biliary tract cancer who hadprogressed on gemcitabine plus cisplatin, and showed improved overall survival withthe addition of FOLFOX. The results of this trial led the National Comprehensive CancerNetwork to recommend FOLFOX as the preferred second-line therapy in the case of diseaseprogression. Additional targeted and immunotherapeutic agents have been approved and recommendedfor patients with biliary tract cancer harbouring specific genetic mutations who haveprogressed on gemcitabine plus cisplatin, including ivosidenib for IDH1-mutated cholangiocarcinoma.
The Lancet Oncology , 2021